news

FDA comments on President Trump’s COVID-19 Emergency Relief Bill

2
SHARES

The bill includes $80 million funding for the US FDA to continue their COVID-19 response efforts and extra powers to modernise over-the-counter drug regulation.

jar of US currency coins next to a wooden gavel and block

On Friday, US President Donald Trump signed into law a $2 trillion emergency relief bill designed to support response efforts for and limit the economic impact of COVID-19. Within the legislation, the US Food and Drug Administration (FDA) was provided $80 million funding to continue their COVID-19 response efforts.

 

ACCESS your FREE COPY

 


This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.

Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.

What you’ll discover:

  • Key trends shaping the pharmaceutical formulation sector
  • Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
  • Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
  • And more!

Don’t miss your chance to access this exclusive report ! Access now – it’s free

According to the FDA, the money will go towards the development of medical countermeasures and vaccines, promoting the advanced manufacturing of medical products and monitoring of the medical product supply chain.

The bill also introduced reforms to modernise how over-the-counter (OTC) drugs are regulated in the US, granting the FDA new authorities that the agency believes will advance their efforts to modernise OTC drug development and review processes. The FDA hopes these changes will advance innovative, safe and effective therapeutic options for consumers and secure a robust OTC marketplace.

In a statement, the FDA Commissioner, Dr Stephen Hahn, revealed: “The FDA is committed to using these new tools to promote innovation and improve the safety and effectiveness of OTC monograph drugs – including products like hand sanitisers and acetaminophen, which are so critical to the public health emergency we face right now. We look forward to providing updates as we implement this important new law.”

Share via
Share via